3상모집 중
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
연구 개요
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder characterized by a persistent feeling of sadness and loss of interest in activities) as compared with psychoactive placebo (does not contain JNJ-54135419) plus SoC in adolescent participants with acute suicidal ideation or behavior.
- 스폰서
- 리드: 얀센(J&J)
- 적응증
- Depressive Disorder, Major
- 중재
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- 목표 등록
- 258명
- 시작일
- 2026-01-08
- 완료(예정)
- 2031-09-15
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.